Plus Therapeutics, Inc.
PSTV
$6.14
$0.549.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.21M | 5.26M | 5.32M | 5.21M | 5.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.21M | 5.26M | 5.32M | 5.21M | 5.82M |
| Cost of Revenue | 8.38M | 7.62M | 8.05M | 9.57M | 10.58M |
| Gross Profit | -3.17M | -2.37M | -2.73M | -4.37M | -4.76M |
| SG&A Expenses | 12.13M | 11.09M | 10.04M | 10.57M | 9.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.51M | 18.71M | 18.09M | 20.14M | 20.52M |
| Operating Income | -15.30M | -13.46M | -12.77M | -14.93M | -14.70M |
| Income Before Tax | -22.39M | -20.58M | -19.03M | -27.12M | -12.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.39 | -20.58 | -19.03 | -27.12 | -12.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.39M | -20.58M | -19.03M | -27.12M | -12.98M |
| EBIT | -15.30M | -13.46M | -12.77M | -14.93M | -14.70M |
| EBITDA | -14.85M | -12.81M | -12.00M | -14.07M | -13.82M |
| EPS Basic | -739.32 | -750.69 | -758.81 | -770.73 | -51.72 |
| Normalized Basic EPS | -596.67 | -603.77 | -608.84 | -617.57 | -32.33 |
| EPS Diluted | -740.11 | -751.47 | -759.69 | -777.29 | -58.29 |
| Normalized Diluted EPS | -597.94 | -605.05 | -610.12 | -614.78 | -29.54 |
| Average Basic Shares Outstanding | 11.76M | 6.57M | 2.58M | 907.00K | 1.06M |
| Average Diluted Shares Outstanding | 18.19M | 13.00M | 9.01M | 1.08M | 1.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |